Atyr PHARMA (NASDAQ:ATYR – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01, Yahoo Finance reports.
Atyr PHARMA Stock Performance
NASDAQ:ATYR traded up $0.04 during trading hours on Wednesday, reaching $1.78. 47,910 shares of the company were exchanged, compared to its average volume of 476,594. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07. The stock has a market capitalization of $122.68 million, a PE ratio of -1.98 and a beta of 1.25. Atyr PHARMA has a twelve month low of $1.08 and a twelve month high of $2.50.
Insider Buying and Selling at Atyr PHARMA
In other news, Director Paul Schimmel acquired 52,300 shares of the stock in a transaction that occurred on Wednesday, July 24th. The shares were bought at an average cost of $1.93 per share, for a total transaction of $100,939.00. Following the acquisition, the director now owns 413,023 shares in the company, valued at approximately $797,134.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.70% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on Atyr PHARMA
Atyr PHARMA Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Further Reading
- Five stocks we like better than Atyr PHARMA
- What is a Dividend King?
- Serve Robotics Is Serving Up a Selling Opportunity
- Why Invest in High-Yield Dividend Stocks?
- Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
- How to Invest in Blue Chip Stocks
- Microsoft Stock: Is Now The Time To Be Greedy?
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.